Status:
RECRUITING
The Neurobiological Effect of 5-HT2AR Modulation
Lead Sponsor:
Gitte Moos Knudsen
Conditions:
Basic Science
Eligibility:
All Genders
18+ years
Phase:
PHASE1
Brief Summary
The investigators wish to investigate neurobiological effects of serotonin 2A receptor modulation in healthy volunteers, contrasting effects of an agonist (psilocybin) and an antagonist (ketanserin). ...
Detailed Description
This project applies an experimental medicine strategy coupled with human functional and molecular neuroimaging to elucidate the effects of 5-HT2A receptor (5-HT2AR) modulation on brain function and m...
Eligibility Criteria
Inclusion
- Inclusion Criteria:
- 1\) Healthy individuals above 18 years of age.
- Exclusion Criteria (For Subprojects 1, 2a, 2b, and 3):
- Presence of or previous primary psychiatric disease (DSM axis 1 or WHO ICD-10 diagnostic classifications) or in first-degree relatives.
- Previous or present neurological condition/disease, significant somatic condition/disease or intake of drugs suspected to influence test results.
- Non-fluent Danish language skills.
- Vision or hearing impairment.
- Previous or present learning disability.
- Pregnancy.
- Breastfeeding.
- Contraindications in regard to MRI scanning.
- Alcohol or drug abuse.
- Allergy to test drugs.
- Participation in studies in which participant has received more than 10 mSv of radiation or other significant exposure to radiation.
- Abnormal ECG or intake of QT prolonging medication.
- Previous significant side-effects in regard to hallucinogenic drugs.
- Use of hallucinogenic drugs 6 months previous to inclusion.
- Blood donation 3 months before and after project participation
- Body weight under 50 kg.
- Plasma ferritin levels outside normal range
- Exclusion Criteria (For Subproject 2c):
- Presence of or previous primary psychiatric disease (DSM IV axis 1 or WHO ICD-10 diagnostic classifications).
- Presence of or previous primary psychiatric disease with psychosis symptoms or hypomania (DSM IV axis 1 \[drug/alcohol abuse/dependence, schizophrenia and other psychoses\] or WHO ICD-10 diagnostic classifications \[F10-29, as well as F30-39 with psychotic symptoms, F60\]) in first-degree relatives (parents or siblings).
- Previous or present neurological condition/disease, significant somatic condition/disease or intake of drugs suspected to influence test results.
- Non-fluent Danish language skills or pronounced vision or hearing impairment.
- Previous or present learning disability.
- Pregnancy.
- Breastfeeding.
- Contraindications in regard to MRI scanning.
- Alcohol or drug abuse.
- Allergy to test drugs.
- Abnormal ECG or intake of QT prolonging medication.
- Previous significant side-effects in regard to hallucinogenic drugs.
- Previous use of hallucinogenic drugs.
- Body weight under 45 kg.
- Ethical concerns regarding the administration of a psychedelic drug.
Exclusion
Key Trial Info
Start Date :
March 3 2017
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
June 1 2030
Estimated Enrollment :
200 Patients enrolled
Trial Details
Trial ID
NCT03289949
Start Date
March 3 2017
End Date
June 1 2030
Last Update
December 16 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Neurobiology Research Unit, Rigshospitalet
Copenhagen, Denmark, 2100